296 related articles for article (PubMed ID: 27001612)
1. The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.
Hillion J; Roy S; Heydarian M; Cope L; Xian L; Koo M; Luo LZ; Kellyn K; Ronnett BM; Huso T; Armstrong D; Reddy K; Huso DL; Resar LMS
Gynecol Oncol; 2016 Jun; 141(3):580-587. PubMed ID: 27001612
[TBL] [Abstract][Full Text] [Related]
2. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.
Tesfaye A; Di Cello F; Hillion J; Ronnett BM; Elbahloul O; Ashfaq R; Dhara S; Prochownik E; Tworkoski K; Reeves R; Roden R; Ellenson LH; Huso DL; Resar LM
Cancer Res; 2007 May; 67(9):3998-4004. PubMed ID: 17483309
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.
Hillion J; Wood LJ; Mukherjee M; Bhattacharya R; Di Cello F; Kowalski J; Elbahloul O; Segal J; Poirier J; Rudin CM; Dhara S; Belton A; Joseph B; Zucker S; Resar LM
Mol Cancer Res; 2009 Nov; 7(11):1803-12. PubMed ID: 19903768
[TBL] [Abstract][Full Text] [Related]
4. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.
Resnick MB; Sabo E; Kondratev S; Kerner H; Spagnoli GC; Yakirevich E
Int J Cancer; 2002 Sep; 101(2):190-5. PubMed ID: 12209997
[TBL] [Abstract][Full Text] [Related]
5. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis.
Schuldenfrei A; Belton A; Kowalski J; Talbot CC; Di Cello F; Poh W; Tsai HL; Shah SN; Huso TH; Huso DL; Resar LM
BMC Genomics; 2011 Nov; 12():549. PubMed ID: 22053823
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
7. HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer.
Greco M; Arcidiacono B; Chiefari E; Vitagliano T; Ciriaco AG; Brunetti FS; Cuda G; Brunetti A
Anticancer Res; 2018 Feb; 38(2):771-778. PubMed ID: 29374701
[TBL] [Abstract][Full Text] [Related]
8. TGF-β1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.
Zhong J; Liu C; Zhang QH; Chen L; Shen YY; Chen YJ; Zeng X; Zu XY; Cao RX
Int J Oncol; 2017 May; 50(5):1567-1578. PubMed ID: 28393241
[TBL] [Abstract][Full Text] [Related]
9. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
[TBL] [Abstract][Full Text] [Related]
10. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
11. The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.
Sumter TF; Xian L; Huso T; Koo M; Chang YT; Almasri TN; Chia L; Inglis C; Reid D; Resar LM
Curr Mol Med; 2016; 16(4):353-93. PubMed ID: 26980699
[TBL] [Abstract][Full Text] [Related]
12. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?
Hillion J; Dhara S; Sumter TF; Mukherjee M; Di Cello F; Belton A; Turkson J; Jaganathan S; Cheng L; Ye Z; Jove R; Aplan P; Lin YW; Wertzler K; Reeves R; Elbahlouh O; Kowalski J; Bhattacharya R; Resar LM
Cancer Res; 2008 Dec; 68(24):10121-7. PubMed ID: 19074878
[TBL] [Abstract][Full Text] [Related]
13. High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.
Gorbounov M; Carleton NM; Asch-Kendrick RJ; Xian L; Rooper L; Chia L; Cimino-Mathews A; Cope L; Meeker A; Stearns V; Veltri RW; Bae YK; Resar LMS
Breast Cancer Res Treat; 2020 Jan; 179(1):25-35. PubMed ID: 31531802
[TBL] [Abstract][Full Text] [Related]
14. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
15. Genomic aberrations in carcinomas of the uterine corpus.
Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of
Palumbo Júnior A; de Sousa VPL; Esposito F; De Martino M; Forzati F; Moreira FCB; Simão TA; Nasciutti LE; Fusco A; Ribeiro Pinto LF; Bessa Pereira Chaves C; Meireles Da Costa N
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31096664
[TBL] [Abstract][Full Text] [Related]
17. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma.
Emoto M; Charnock-Jones DS; Licence DR; Ishiguro M; Kawai M; Yanaihara A; Saito T; Hachisuga T; Iwasaki H; Kawarabayashi T; Smith SK
Gynecol Oncol; 2004 Dec; 95(3):474-82. PubMed ID: 15581949
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
19. High mobility group A1 and cancer: potential biomarker and therapeutic target.
Shah SN; Resar LM
Histol Histopathol; 2012 May; 27(5):567-79. PubMed ID: 22419021
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group A1 protein: a new coregulator of peroxisome proliferator-activated receptor-γ-mediated transrepression in the vasculature.
Bloch M; Prock A; Paonessa F; Benz V; Bähr IN; Herbst L; Witt H; Kappert K; Spranger J; Stawowy P; Unger T; Fusco A; Sedding D; Brunetti A; Foryst-Ludwig A; Kintscher U
Circ Res; 2012 Feb; 110(3):394-405. PubMed ID: 22207709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
